This lexicon explains some of the terms used to talk about trials designed to test new HIV prevention tools.
HIV Prevention Trial Terms: An advocate’s guide
From Proof-of-Concept to Prevention Phenomenon in Five Years
This timeline, first appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows PrEP going from proof-of-concept to prevention phenomenon in five years and can be used to anticipate and speed action on the next generation of ARV-based prevention options.
Layers of Biomedical HIV Prevention Trial Stakeholders
Various stakeholders may influence or be affected by a biomedical HIV prevention trial. Stakeholders include trial participants and other community stakeholders as well as a broader range of national and international stakeholders.
Excerpted from the Good Participatory Practice (GPP) Guidelines, which provide trial funders, sponsors, and implementers with systematic guidance on how to effectively engage with all stakeholders in the design and conduct of biomedical HIV prevention trials. More at avac.org/gpp.
Advocacy in Uncertain Times: A call to action
AVAC’s report for HIV Vaccine Awareness Day on the state of the HIV vaccine research and development field, including key priorities for advancing research and sustaining support.
Financing the Search: Then and now
Funding for vaccines research in 1997 and 2016, segmented by government and other sector spending.
Number of Vaccines Trials: Then and now
A snapshot of the number of vaccine trials conducted globally between 1997 and 2017.
HIV-Specific Neutralizing Antibodies: A guide to targets and candidates
A detailed graphic describing the status of pre-clinical and clinical work around relevant bNAbs today.
Where Does Oral PrEP Fit in to Vaccine and AMP Trials?
A global map showing current efficacy trial countries and their status of PrEP implementation.
Vaccine Approaches in Early-Phase Development
An outline of various approaches to vaccine development that are in earlier phase research, e.g., phase I or II trials; development pathways for these candidates are uncertain at this time.
Vaccines and Antibodies on Efficacy Pathways
A timeline of current efficacy programs for vaccines and antibodies, highlighting the P5 program testing pox-protein candidates, the Janssen program testing mosaic-based candidates, and the AMP studies testing the antibody VRC01.